Viatris Inc. (VTRS)

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

Why Pacira BioSciences Skyrocketed Today

Viatris to Buy Pacira BioSciences for $1.65 Billion

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

VTRS vs. AVTR: Which Stock Is the Better Value Option?

Should Value Investors Buy Viatris (VTRS) Stock?

Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?

Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

Here's Why Viatris (VTRS) is a Strong Value Stock